MedPath

NIPRO CORPORATION

🇯🇵Japan
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

14

Active:3
Completed:5

Trial Phases

1 Phases

Phase 3:4

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials

Phase 3
4 (100.0%)
No trials found

News

Samsung Bioepis Partners with NIPRO to Commercialize Biosimilars in Japan, Including Ustekinumab Candidate

Samsung Bioepis has entered into a strategic partnership with NIPRO Corporation for the development and commercialization of multiple biosimilar candidates in Japan, including SB17, a ustekinumab biosimilar.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.